Immatics Provides Update on IMA204 ACTengine® Cell Therapy Program Targeting the Tumor Microenvironment
- IMA204 ACTengine® cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expressed at high copy numbers in tumor stroma across many solid cancers
- Two affinity-enhanced TCR candidates designed using Immatics’ proprietary XCEPTOR™ platform demonstrates high specificity and potency; one of the candidates shows full functionality also in CD4+ T cells without requirement for a CD8 co-receptor
- Submission of IND application to FDA for IMA204 remains on track for 2021
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its fourth ACTengine® cell therapy program, IMA204. IMA204 is designed to address a novel target, COL6A3 exon 6, which is highly expressed in the stroma of a large number of solid tumors. Immatics will discuss the IMA204 preclinical data at the Hanson Wade CAR-TCR Digital Week on September 14th.